NICE Recommends GSK's Nucala for Uncontrolled COPD

Author: Ekin Özkan…

NICE Recommends GSK's Nucala for Uncontrolled COPD

The UK's National Institute for Health and Care Excellence (NICE) has recommended GSK's Nucala (mepolizumab) as an add-on treatment for some patients with uncontrolled chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype for use in the NHS.

Details of the Decision

NICE stated that Nucala is effective in reducing COPD exacerbations in specific patient groups. This recommendation is considered a promising development for patients whose COPD remains uncontrolled despite standard therapy.

Patient Population

The recommendation covers patients with high blood eosinophil counts and frequent exacerbations. Nucala will be used in addition to existing treatments.

Impacted Symbols

Symbols affected by this headline and their sentiment signals

GSKPositive

GSK plc

NICE recommendation will directly increase Nucala's usage in the NHS, positively impacting GSK's market share and revenues in COPD treatment.

Impact score85%

The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.

More Headlines